EdwardNLibbyMD

Physician

Dr. Libby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4727 Edgeware Road
San Diego, CA 92116
Phone+1 505-259-7714

Fax+1 505-259-7714

Dr. Libby received his B.S. from the University of Texas at El Paso and his M.D. from the University of Texas Health Science Center at Houston. He completed his Internal Medicine residency and chief residency at the University of New Mexico(UNM) in Albuquerque. He was a Fellow in Hematology at UNM and at UNC Chapel Hill.

University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
University of New Mexico School of MedicineResidency, Internal Medicine, 1984 - 1987
McGovern Medical School at UTHealthClass of 1984

PubMed

32 citations
Dismounting the MDR horse
Edward N. Libby, Robert Hromas
Blood. 2010-11-18
5 citations
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospe...
Andrew J. Cowan, Philip A. Stevenson, Damian J. Green, Sherilyn A. Tuazon, Edward N. Libby
Transplantation and Cellular Therapy. 2021-04-22
468 citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka
The Lancet. Oncology. 2020-02-01

Abstracts/Posters

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018